Mutation analysis in Spanish patients with hereditary hemorrhagic telangiectasia: Deficient endoglin up-regulation in activated monocytes

Clinical Chemistry

Volumn 50, Issue 11, 2004, Pages 2003-2011

  Sanz Rodriguez, Francisco ^a,b   Fernandez L, Africa ^a   Zarrabeitia, Roberto ^c   Perez Molino, Alfonso ^c   Ramírez, Jose R ^d   Coto, Eliecer ^e   Bernabeu, Carmelo ^a   Botella, Luisa M ^a  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c HOSPITAL SIERRALLANA   (Spain)

^d HOSPITAL CENTRAL DE LA DEFENSA GÓMEZ ULLA   (Spain)

^e HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR; COMPLEMENTARY DNA; ENDOGLIN; GENOMIC DNA; MONOCLONAL ANTIBODY; PROTEIN KINASE;

ALK1 GENE; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; ENG GENE; FLOW CYTOMETRY; GENE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; MONOCYTE; RENDU OSLER WEBER DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPAIN;

ANTIGENS, CD; FLOW CYTOMETRY; HUMANS; MONOCYTES; MUTATION; RECEPTORS, CELL SURFACE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPAIN; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; UP-REGULATION; VASCULAR CELL ADHESION MOLECULE-1;

EID: 7044246040     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2004.035287     Document Type: Article

References (40)

1. Guttmacher AE, Marchuk DA, White RI Jr. Hereditary hemorrhagic telangiectasia. N Engl J Med 1995;333:918-24.
2. Haitjema T, Westermann CJ, Overtoom TT, Timmer R, Disch F, Mauser H, et al. Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease): new insights in pathogenesis, complications, and treatment. Arch Intern Med 1996;156:714-9.
3. Marchuk D, Lux A. Hereditary hemorrhagic telangiectasia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease, Vol. IV, 8th ed. New York: McGraw-Hill Medical Publishing Division, 2001:5419-543.
4. Plauchu H, de Chadarevian JP, Bideau A, Robert JM. Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet 1989;32:291-7.
5. Shovlin CL, Letarte M. Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms. Thorax 1999;54:714-29.
6. Fernandez-Ruiz E, St-Jacques S, Bellon T, Letarte M, Bernabeu C. Assignment of the human endoglin gene (END) to 9q34→qter. Cytogenet Cell Genet 1993;64:204-7.
7. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, et al. Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994;8:345-51.
8. Lastres P, Bellon T, Cabanas C, Sanchez-Madrid F, Acevedo A, Gougos A, et al. Regulated expression on human macrophages of endoglin; an Arg-Gly-Asp-containing surface antigen. Eur J Immunol 1992;22:393-7.
9. Pece-Barbara N, Cymerman U, Vera S, Marchuk DA, Letarte M. Expression analysis of four endoglin missense mutations suggests that haploinsufficiency is the predominant mechanism for hereditary hemorrhagic telangiectasia type 1. Hum Mol Genet 1999;8:2171-81.
10. Cymerman U, Vera S, Pece-Barbara S, Bourdeau A, White R Jr, Dunn J, et al. Identification of hereditary hemorrhagic telangiectasia type 1 in newborns by protein expression and mutation analysis of endoglin. Pediatric Res 2000;47:24-35.
11. Lastres P, Letamendia A, Zhang H, Rius C, Almendro N, Raab U, et al. Endoglin modulates cellular responses to TGF-β 1. J Cell Biol 1996;133:1109-21.
12. Letamendia A, Lastres P, Botella LM, Raab U, Langa C, Velasco B, et al. Role of endoglin in cellular responses to transforming growth factor-β. A comparative study with β-glycan. J Biol Chem 1998;273:33011-9.
13. Guerrero-Esteo M, Lastres P, Letamendia A, Perez-Alvarez MJ, Langa C, Lopez LA, et al. Endoglin overexpression modulates cellular morphology, migration, and adhesion of mouse fibroblasts. Eur J Cell Biol 1999;78:614-23.
14. Conley BA, Koleva R, Smith JD, Kacer D, Zhang D, Bernabeu C, et al. Endoglin controls cell migration and composition of focal adhesions: function of the cytosolic domain. J Biol Chem 2004;279:27440-9.
15. Johnson D, Berg JN, Baldwin MA, Gallione CJ, Marondel I, Yoon S, et al. Mutations in the activin receptor-like kinase 1 gene in hereditary hemorrhagic telangiectasia type 2. Nat Genet 1996;13:189-95.
16. Johnson DW, Berg JN, Gallione CJ, McAllister KA, Warner JP, Helmbold EA, et al. A second locus for hereditary hemorrhagic telangiectasia maps to chromosome 12. Genome Res 1995;5:21-8.
17. Siegel PM, Massague J. Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nat Rev Cancer 2003;3:807-20.
18. Attisano L, Wrana JL. Smads as transcriptional co-modulators. Curr Opin Cell Biol 2000;12:235-43.
19. Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000;91:66-7.
20. Pece N, Vera S, Cymerman U, White RJ, Wrana JL, Letarte M. Mutant endoglin in hereditary hemorrhagic telangiectasia type 1 is transiently expressed intracellularly and is not a dominant negative. J Clin Invest 1997;100:2568-79.
21. Shovlin CL, Hughes JM, Scott J, Seidman M, Seidman JG. Characterization of endoglin and identification of novel mutations in hereditary hemorrhagic telangiectasia. Am J Hum Genet 1997;61:68-79.
22. Abdalla SA, Pece-Barbara N, Vera S, Tapia E, Paez E, Bernabeu C, et al. Analysis of ALK1 and endoglin in newborns from families with hereditary hemorrhagic telangiectasia type 2. Hum Mol Genet 2000;9:1227-37.
23. Abdalla SA, Geisthoff UW, Bonneau D, Plauchu H, McDonald J, Kennedy S, et al. Visceral manifestations in hereditary haemorrhagic telangiectasia type 2. J Med Genet 2003;40:494-502.
24. Pichuantes S, Vera S, Bourdeau A, Pece N, Kumar S, Wayner EA, et al. Mapping epitopes to distinct regions of the extracellular domain of endoglin using bacterially expressed recombinant fragments. Tissue Antigens 1997;50:265-76.
25. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P. Balancing the activation state of the endothelium via two distinct TGF-β type I receptors. EMBO J 2002;21:1743-53.
26. Panchenko MP, Williams MC, Brody JS, Yu Q. Type I receptor serine-threonine kinase preferentially expressed in pulmonary blood vessels. Am J Physiol 1996;270(4 Pt 1):L547-58.
27. Hazouard E, Ritz-Quillacq L, Herbreteau D, Legras A, Dequin PF, Ginies G. Weber-Rendu-Osler disease: pulmonary arterio-venous malformation with shunt disclosed after 5 occurrences of purulent meningococcal encephalitis. Rev Mal Respir 1999;16:95-7.
28. Dong SL, Reynolds SF, Steiner IP. Brain abscess in patients with hereditary hemorrhagic telangiectasia: case report and literature review. J Emerg Med 2003;20:247-51.
29. Duval X, Djendli S, Le Moing V, Longuet P, Barry B, Leport C, et al. Recurrent Staphylococcus aureus extracerebral infections complicating hereditary hemorrhagic telangiectasia (Osler-Rendu-Weber disease). Am J Med 2001;110:671-2.
30. Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahoe PK, et al. Activin receptor-like kinase 1 modulates transforming growth factor-β 1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci U S A 2000;9:2626-31.
31. Goumans MJ, Lebrin F, Valdimarsdottir G. Controlling the angiogenic switch: a balance between two distinct TGF-β receptor signalling pathways. Trends Cardiovasc Med 2003;13:301-7.
32. Rius C, Smith JD, Almendro N, Langa C, Botella LM, Marchuk DA, et al. Cloning of the promoter region of human endoglin, the target gene for hereditary hemorrhagic telangiectasia type 1. Blood 1998;92:4677-90.
33. Botella LM, Sanchez-Elsner T, Rius C, Corbi A, Bernabeu C. Identification of a critical Sp1 site within the endoglin promoter and its involvement in the transforming growth factor-β stimulation. J Biol Chem 2001;276:34486-94.
34. Cheifetz S, Bellón T, Calés C, Vera S, Bernabeu C, Massagué J, et al. Endoglin is a component of the transforming growth factor-β receptor system in human endothelial cells. J Biol Chem 1992;267:19027-30.
35. Ota T, Fujii M, Sugizaki T, Ishii M, Miyazawa K, Aburatani H, et al. Targets of transcriptional regulation by two distinct type I receptors for transforming growth factor-β in human umbilical vein endothelial cells. J Cell Physiol 2002;193:299-318.
36. Karlsson S, ten Dijke P. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFβ/ALK5 signaling. Mol Cell 2003;12:817-28.
37. Sanchez-Elsner T, Botella LM, Velasco B, Langa C, Bernabeu C. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-β pathways. J Biol Chem 2002;277:43799-808.
38. Botella LM, Sanchez-Elsner T, Sanz-Rodriguez F, Kojima S, Shimada J, Guerrero-Esteo M, et al. Transcriptional activation of endoglin and transforming growth factor-β signaling components by cooperative interaction between Sp1 and KLF6: their potential role in the response to vascular injury. Blood 2002;100:4001-10.
39. Li C, Issa R, Kumar P, Hampson IN, Lopez-Novoa JM, Bernabeu C, et al. CD105 prevents apoptosis in hypoxic endothelial cells. J Cell Sci 2003;116:2677-85.
40. Braverman IM, Keh A, Jacobson BS. Ultrastructure and three-dimensional organization of the telangiectasias of hereditary hemorrhagic telangiectasia. J Invest Dermatol 1990;95:422-7.